Blog List

Dr. David Rubin: MAP, the Microbiome and Crohn’s Treatment

A welcome surprise to the symposium lineup, Dr. David Rubin, section chief of the department of gastroenterology at the University of Chicago Medical Center, discusses the current state of Crohn’s disease and outlines some of the available treatments. While he prescribes Anti-MAP therapy for some of his patients, he takes an individualistic approach to care, utilizing all treatment available to manage his patients’ disease. Interesting information about the role of the gut microbiome, the genetic profile of Crohn’s patients and how Dr. Rubin became interested in gastroenterology are included. He admits that the search for a cure should be a goal of current IBD research. Don’t miss the insightful audience questions!

[button link=”http://humanpara.org/the-current-state-of-crohns-treatment-dr-david-rubin” type=”big” color=”orange”] Watch the Video[/button]

John Aitken – Antibiotics

AntibioticsWe are at the dawning of a new era in the use of antibiotics. For some 20 years there have been attempts to use antibiotics in the treatment of Crohn’s disease. Although most trials have delivered mixed results, this direction has been reinforced by the association of Mycobacterium avium ssp paratuberculosis (MAP) with Crohn’s disease. The main principle of judicious and effective antibiotic usage has been the targeting of the suspected pathogen with a therapy that is both specific and directed.  This has been a difficult job, as there has been, up to now, no protocol that will ensure the reliable isolation of the pathogen from the patient. The model that is used for new compounds against MAP-associated organisms is directly related to the proven therapies for tuberculosis, and this has been a wise model to follow.

[button link=”http://thecrohnsinfection.org/john-aitken-antibiotics/” type=”big”] Read the Full Article[/button]

Post Symposium Thoughts and New Forum | Web Admin

Virus MicrographI know everyone is patiently awaiting the video replay from the symposium last week, and we hope to get it on the website this week! Also coming soon: a MAP forum partnership where you can share your stories, treatments, theories and ideas about everything MAP. Sign up and stay connected to the latest developments and others like you. While we wait for the video, here are a few thoughts from a humble audience member.

[button link=”http://thecrohnsinfection.org/moderator-post-symposium-thoughts-and-new-forum” type=”big”] Read the Full Article[/button]

Crohn’s Disease Core Research Pack

About Crohn’s Treatments Traditional Treatments Prednisone 6-MP and AZA Methotrexate Remicade HUMIRA Biosimilars Anti-MAP (AMAT) Therapy Anti-MAP Q&A Clinical Trials Patient Stories A Pediatric Story 3 Stories of Hope David Elle Jay Jen Roy M. Resources Core Research Pack CD vs. UC Chart The MAP ...

Dr. William Chamberlin | FepiBro Part 2

Immune Modulating Drug Stimulates Innate Immunity, Down-Regulates Unproductive Inflammation and Promotes Th1 Immunity People have asked for more information on Formulated EpiBro (FepiBro). A formulation of 16-bromoepiandrosterone (Epi-Br) was originally developed and investigated under the name HE2000.  There is extensive literature on its activity against infectious diseases. It underwent human trials as an immune modulating drug designed to combat the major infectious diseases in the “Developing World.” The HE2000 formula demonstrated activity against HIV/AIDS, malaria and tuberculosis in nine human trials. It was shown to be safe and effective. Read on to see why it wasn’t further developed and why it could now help Crohn’s disease patients.

Read the Full Article